Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 25, 2023

SELL
$0.34 - $0.45 $1,156 - $1,530
-3,400 Reduced 8.04%
38,886 $13,000
Q1 2023

Apr 14, 2023

BUY
$0.4 - $1.08 $880 - $2,376
2,200 Added 5.49%
42,286 $19,000
Q4 2022

Feb 08, 2023

BUY
$0.66 - $38.7 $4,139 - $242,726
6,272 Added 18.55%
40,086 $28,000
Q3 2022

Oct 25, 2022

SELL
$1.06 - $36.9 $20,613 - $717,594
-19,447 Reduced 36.51%
33,814 $40,000
Q2 2022

Aug 12, 2022

BUY
$4.35 - $5.76 $4,393 - $5,817
1,010 Added 1.93%
53,261 $247,000
Q1 2022

May 11, 2022

BUY
$3.92 - $6.25 $93,107 - $148,450
23,752 Added 83.34%
52,251 $285,000
Q4 2021

Feb 08, 2022

BUY
$5.52 - $8.42 $22,841 - $34,841
4,138 Added 16.99%
28,499 $164,000
Q3 2021

Nov 02, 2021

BUY
$7.05 - $9.48 $32,042 - $43,086
4,545 Added 22.94%
24,361 $190,000
Q2 2021

Aug 11, 2021

BUY
$8.4 - $9.99 $26,544 - $31,568
3,160 Added 18.97%
19,816 $179,000
Q1 2021

May 14, 2021

SELL
$8.92 - $15.5 $478,888 - $832,148
-53,687 Reduced 76.32%
16,656 $153,000
Q4 2020

Feb 12, 2021

BUY
$8.89 - $13.5 $625,349 - $949,630
70,343 New
70,343 $700,000

About PolyPid Ltd.


  • Ticker PYPD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 19,551,200
  • Market Cap $64.5M
  • Description
  • PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well a...
More about PYPD
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.